AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS 113_CD Additional_JJ Information_NN for_IN US_NNP Investors_NNPS Introduction_NNP and_CC liabilities_NNS of_IN Astra_NNP was_VBD recorded_VBN as_IN On_IN disposal_NN of_IN a_DT business_NN ,_, the_DT gain_NN or_CC loss_NN The_DT accompanying_VBG consolidated_JJ Financial_NNP goodwill_NN ._.
The_DT amount_NN allocated_VBN to_TO in-process_JJ under_IN US_NNP GAAP_NNP may_MD differ_VB from_IN that_DT under_IN Statements_NNP included_VBD in_IN this_DT Annual_JJ Report_NNP research_NN and_CC development_NN was_VBD ,_, as_IN required_VBN UK_NNP GAAP_NNP due_JJ principally_RB to_TO goodwill_NN are_VBP prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
by_IN US_NNP GAAP_NNP ,_, expensed_VBD immediately_RB in_IN the_DT capitalized_JJ and_CC amortised_JJ ,_, together_RB with_IN the_DT There_EX are_VBP certain_JJ significant_JJ differences_NNS first_RB reporting_VBG period_NN after_IN the_DT business_NN appropriate_JJ share_NN of_IN other_JJ differences_NNS between_IN UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP which_WDT combination_NN ._.
Fair_NNP value_NN adjustments_NNS to_TO the_DT between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS affect_VBP AstraZenecas_NNP net_JJ income_NN and_CC recorded_VBN amount_NN of_IN inventory_NN were_VBD recognized_VBN previously_RB ._.
shareholders_NNS equity_NN and_CC ,_, on_IN pages_NNS 113_CD to_TO expensed_VBN in_IN the_DT period_NN the_DT inventory_NN was_VBD 123_CD ,_, additional_JJ information_NN under_IN US_NNP GAAP_NNP utilised_VBD ._.
Additional_JJ amortisation_NN and_CC Capitalisation_NNP of_IN interest_NN is_VBZ set_VBN out_RP as_IN follows_VBZ :_: depreciation_NN have_VBP also_RB been_VBN recorded_VBN in_IN AstraZeneca_NNP does_VBZ not_RB capitalize_VB interest_NN in_IN its_PRP$ respect_NN of_IN the_DT fair_JJ value_NN adjustments_NNS to_TO UK_NNP GAAP_NNP Financial_NNP Statements_NNP ._.
US_NNP GAAP_NNP summary_NN of_IN differences_NNS between_IN UK_NNP tangible_JJ and_CC intangible_JJ assets_NNS and_CC the_DT requires_VBZ interest_NN incurred_VBN as_IN part_NN of_IN the_DT cost_NN and_CC US_NNP GAAP_NNP accounting_NN principles_NNS :_: resulting_VBG goodwill_NN ._.
of_IN constructing_VBG fixed_JJ assets_NNS to_TO be_VB capitalized_VBN page_NN 113_CD and_CC amortised_VBN over_IN the_DT life_NN of_IN the_DT asset_NN ._.
In_IN the_DT consolidated_JJ Financial_NNP Statements_NNP net_JJ income_NN :_: page_NN 116_CD prepared_VBN under_IN UK_NNP GAAP_NNP ,_, goodwill_NN arising_VBG Dividends_NNS on_IN acquisitions_NNS made_VBN prior_RB to_TO 1_CD January_NNP 1998_CD Under_IN UK_NNP GAAP_NNP ,_, Ordinary_NNP Share_NNP dividends_NNS US_NNP GAAP_NNP condensed_JJ consolidated_JJ accounted_VBN for_IN under_IN the_DT purchase_NN method_NN proposed_VBN are_VBP provided_VBN for_IN in_IN the_DT year_NN in_IN statement_NN of_IN operations_NNS :_: page_NN 117_CD has_VBZ been_VBN eliminated_VBN against_IN shareholders_NNS respect_NN of_IN which_WDT they_PRP are_VBP recommended_VBN by_IN equity_NN ._.
Under_IN the_DT requirements_NNS of_IN UK_NNP the_DT Board_NNP of_IN Directors_NNS for_IN approval_NN by_IN the_DT US_NNP GAAP_NNP statement_NN of_IN comprehensive_JJ Financial_NNP Reporting_NNP Standard_NNP 10_CD Goodwill_NNP shareholders_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ income_NN :_: page_NN 117_CD and_CC Intangible_NNP Assets_NNPS ,_, goodwill_NN on_IN dividends_NNS are_VBP not_RB provided_VBN for_IN until_IN declared_VBN acquisitions_NNS made_VBN after_IN 1_CD January_NNP 1998_CD is_VBZ by_IN the_DT Board_NNP ._.
stock_NN compensation_NN :_: page_NN 118_CD capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ life_NN which_WDT is_VBZ generally_RB presumed_VBN not_RB to_TO Deferred_JJ taxation_NN pension_NN and_CC post-retirement_NN benefits_NNS :_: exceed_VB 20_CD years_NNS ._.
UK_NNP GAAP_NNP requires_VBZ that_IN on_IN Deferred_JJ taxation_NN is_VBZ provided_VBN on_IN a_DT full_JJ liability_NN page_NN 119_CD subsequent_JJ disposal_NN or_CC termination_NN of_IN a_DT basis_NN under_IN US_NNP GAAP_NNP ,_, which_WDT permits_VBZ previously_RB acquired_VBN business_NN ,_, any_DT goodwill_NN deferred_VBN tax_NN assets_NNS to_TO be_VB recognized_VBN if_IN their_PRP$ taxation_NN :_: page_NN 121_CD previously_RB taken_VBN directly_RB to_TO shareholders_NNS realisation_NN is_VBZ considered_VBN to_TO be_VB more_RBR likely_JJ equity_NN is_VBZ then_RB charged_VBN in_IN the_DT income_NN than_IN not_RB ._.
Under_IN current_JJ UK_NNP GAAP_NNP ,_, full_JJ shareholders_NNS equity_NN :_: page_NN 122_CD statement_NN against_IN the_DT profit_NN or_CC loss_NN on_IN provision_NN is_VBZ also_RB made_VBN although_IN there_EX are_VBP a_DT disposal_NN or_CC termination_NN ._.
Up_IN until_IN 1_CD January_NNP number_NN of_IN different_JJ bases_NNS on_IN which_WDT this_DT acquired_VBN intangible_JJ assets_NNS and_CC goodwill_NN :_: 2002_CD ,_, under_IN US_NNP GAAP_NNP ,_, goodwill_NN was_VBD calculation_NN is_VBZ made_VBN ,_, for_IN example_NN rolled_VBD over_IN page_NN 122_CD required_VBN to_TO be_VB capitalized_VBN and_CC amortised_VBN ._.
Now_RB ,_, instead_RB of_IN being_VBG amortised_VBN ,_, goodwill_NN is_VBZ US_NNP GAAP_NNP condensed_JJ consolidated_JJ tested_VBN annually_RB for_IN impairment_NN ._.
Amortisation_NNP Pension_NNP and_CC post-retirement_JJ benefits_NNS statement_NN of_IN cash_NN flows_NNS :_: page_NN 123_CD charged_VBN under_IN UK_NNP GAAP_NNP is_VBZ added_VBN back_RB in_IN There_EX are_VBP four_CD main_JJ differences_NNS between_IN the_DT reconciliation_NN of_IN net_JJ income_NN ._.
The_DT current_JJ UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP in_IN Differences_NNS between_IN UK_NNP and_CC US_NNP intangible_JJ recognized_VBN as_IN assembled_VBN accounting_NN for_IN pension_NN costs_NNS :_: accounting_NN principles_NNS workforce_NN has_VBZ been_VBN reclassified_VBN as_IN goodwill_NN ._.
i_FW US_PRP GAAP_NNP requires_VBZ measurements_NNS of_IN Purchase_NN accounting_NN adjustments_NNS Identifiable_JJ intangible_JJ assets_NNS ,_, which_WDT plan_VBP assets_NNS and_CC obligations_NNS to_TO be_VB made_VBN Under_IN UK_NNP GAAP_NNP ,_, the_DT merger_NN of_IN Astra_NNP and_CC principally_RB include_VBP patents_NNS ,_, know-how_NN and_CC as_RB at_IN the_DT date_NN of_IN the_DT financial_JJ statements_NNS Zeneca_NNP was_VBD accounted_VBN for_IN as_IN a_DT merger_NN of_IN product_NN registrations_NNS ,_, are_VBP amortised_VBN over_IN or_CC a_DT date_NN not_RB more_RBR than_IN three_CD months_NNS equals_VBZ pooling-of-interests_NNS ._.
Under_IN US_NNP their_PRP$ estimated_VBN useful_JJ lives_NNS which_WDT vary_VBP prior_RB to_TO that_DT date_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, GAAP_NNP the_DT merger_NN was_VBD accounted_VBN for_IN as_IN the_DT between_IN five_CD years_NNS and_CC 20_CD years_NNS with_IN a_DT calculations_NNS may_MD be_VB based_VBN on_IN the_DT results_NNS acquisition_NN of_IN Astra_NNP by_IN Zeneca_NNP using_VBG weighted_JJ average_JJ life_NN of_IN approximately_RB 13_CD of_IN the_DT latest_JJS actuarial_JJ valuation_NN :_: purchase_NN accounting_NN ._.
accounting_NN ,_, the_DT cost_NN of_IN the_DT investment_NN is_VBZ ii_FW US_PRP GAAP_NNP mandates_VBZ a_DT particular_JJ calculated_VBN at_IN the_DT market_NN value_NN of_IN the_DT shares_NNS At_IN 31_CD December_NNP 2003_CD and_CC 2002_CD ,_, actuarial_JJ method_NN the_DT projected_VBN unit_NN issued_VBN together_RB with_IN other_JJ incidental_JJ costs_NNS shareholders_NNS equity_NN includes_VBZ capitalized_JJ credit_NN method_NN and_CC requires_VBZ that_IN each_DT and_CC the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT acquired_VBN goodwill_NN of_IN $_$ 15,306_CD m_NN and_CC $_$ 13,647_CD m_NN significant_JJ assumption_NN necessary_JJ to_TO entity_NN are_VBP recorded_VBN at_IN fair_JJ value_NN ._.
As_IN a_DT result_NN of_IN respectively_RB net_JJ of_IN amortisation_NN and_CC determine_VB annual_JJ pension_NN costs_NNS reflects_VBZ the_DT fair_JJ value_NN exercise_NN ,_, increases_NNS in_IN the_DT values_NNS impairment_NN of_IN $_$ 2,596_CD m_NN and_CC $_$ 2,314_CD m_NN and_CC best_JJS estimates_NNS solely_RB with_IN regard_NN to_TO that_DT of_IN Astras_NNP tangible_JJ fixed_VBN assets_NNS and_CC inventory_NN capitalized_JJ identifiable_JJ intangible_JJ assets_NNS of_IN individual_JJ assumption_NN ._.
UK_NNP GAAP_NNP does_VBZ were_VBD recognized_VBN and_CC values_VBZ attributed_VBN to_TO $_$ 9,536_CD m_NN and_CC $_$ 9,526_CD m_NN respectively_RB net_JJ of_IN not_RB mandate_VB a_DT particular_JJ method_NN ,_, but_CC their_PRP$ in-process_JJ research_NN and_CC development_NN ,_, amortisation_NN and_CC impairment_NN of_IN $_$ 6,739_CD m_NN requires_VBZ that_IN the_DT method_NN and_CC existing_VBG products_NNS and_CC assembled_VBN workforce_NN ,_, and_CC $_$ 4,807_CD m._FW Goodwill_NNP on_IN businesses_NNS assumptions_NNS taken_VBN as_IN a_DT whole_JJ should_MD be_VB together_RB with_IN appropriate_JJ deferred_VBN taxation_NN disposed_VBN of_IN is_VBZ charged_VBN to_TO the_DT gain_NN or_CC loss_NN on_IN compatible_JJ and_CC lead_JJ to_TO the_DT actuarys_NNS best_JJS effects_NNS ._.
The_DT difference_NN between_IN the_DT cost_NN of_IN disposal_NN ._.
estimate_NN of_IN the_DT cost_NN of_IN providing_VBG the_DT investment_NN and_CC the_DT fair_JJ value_NN of_IN the_DT assets_NNS benefits_NNS promised_VBD :_: AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 114_CD Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP Derivative_NNP instruments_NNS and_CC hedging_VBG d_SYM tax_NN paid_VBN :_: e_LS capital_NN expenditure_NN and_CC accounting_NN principles_NNS continued_VBD activities_NNS financial_JJ investment_NN :_: f_LS acquisitions_NNS and_CC Under_IN US_NNP GAAP_NNP ,_, all_DT derivative_JJ instruments_NNS disposals_NNS :_: g_VB dividends_NNS paid_VBN to_TO shareholders_NNS :_: iii_FW under_IN US_NNP GAAP_NNP ,_, a_DT negative_JJ pension_NN cost_NN should_MD be_VB recognized_VBN as_IN assets_NNS or_CC liabilities_NNS in_IN h_JJ management_NN of_IN liquid_JJ resources_NNS :_: and_CC may_MD arise_VB where_WRB a_DT significant_JJ the_DT balance_NN sheet_NN at_IN fair_JJ value_NN ._.
SFAS_NNP 95_CD requires_VBZ only_RB three_CD unrecognised_JJ net_JJ asset_NN or_CC gain_NN exists_VBZ at_IN losses_NNS are_VBP recognized_VBN in_IN net_JJ income_NN unless_IN categories_NNS of_IN cash_NN flow_NN activity_NN being_VBG the_DT time_NN of_IN implementation_NN ._.
This_DT is_VBZ they_PRP are_VBP regarded_VBN as_IN hedges_NNS ._.
Under_IN UK_NNP a_DT operating_NN :_: b_NN investing_NN :_: and_CC c_NN financing_NN ._.
required_VBN to_TO be_VB amortised_VBN on_IN a_DT straightGAAP_NNP ,_, these_DT instruments_NNS are_VBP measured_VBN at_IN line_NN basis_NN over_IN the_DT average_JJ remaining_VBG cost_NN and_CC gains_NNS or_CC losses_NNS deferred_VBN until_IN the_DT Cash_NN flows_VBZ from_IN taxation_NN ,_, returns_NNS on_IN service_NN period_NN of_IN employees_NNS ._.
Under_IN UK_NNP underlying_VBG transactions_NNS occur_VBP ._.
investments_NNS and_CC servicing_NN of_IN finance_NN and_CC GAAP_NNP ,_, AstraZenecas_NNP policy_NN is_VBZ not_RB to_TO dividends_NNS received_VBN from_IN joint_JJ ventures_NNS and_CC recognize_VB pension_NN credits_NNS in_IN its_PRP$ Financial_JJ Deferred_JJ income_NN associates_NNS under_IN FRS_NNP 1_CD would_MD be_VB included_VBN Statements_NNP unless_IN a_DT refund_NN of_IN ,_, or_CC Under_IN UK_NNP GAAP_NNP ,_, profits_NNS or_CC losses_NNS from_IN the_DT as_RB operating_VBG activities_NNS under_IN SFAS_NNP 95_CD :_: capital_NN reduction_NN in_IN ,_, contributions_NNS is_VBZ likely_JJ :_: and_CC sale_NN of_IN product_NN related_VBN intangible_JJ assets_NNS are_VBP expenditure_NN and_CC financial_JJ investment_NN and_CC generally_RB taken_VBN to_TO other_JJ operating_NN income_NN at_IN acquisitions_NNS and_CC disposals_NNS would_MD be_VB iv_VBN under_IN US_NNP GAAP_NNP ,_, a_DT minimum_JJ pension_NN disposal_NN and_CC are_VBP stated_VBN after_IN taking_VBG account_NN included_VBD as_IN investing_VBG activities_NNS :_: and_CC liability_NN is_VBZ recognized_VBN through_IN other_JJ of_IN product_NN disposal_NN costs_NNS and_CC costs_NNS of_IN minor_JJ distributions_NNS would_MD be_VB included_VBN as_IN a_DT comprehensive_JJ income_NN in_IN certain_JJ outstanding_JJ obligations_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, financing_NN activity_NN under_IN SFAS_NNP 95_CD ._.
Under_IN circumstances_NNS when_WRB there_EX is_VBZ a_DT deficit_NN of_IN such_JJ profits_NNS are_VBP deferred_VBN and_CC recognized_VBN in_IN FRS_NNP 1_CD cash_NN comprises_VBZ cash_NN in_IN hand_NN and_CC plan_NN assets_NNS relative_JJ to_TO the_DT accumulated_VBN the_DT income_NN statement_NN in_IN subsequent_JJ periods_NNS deposits_NNS repayable_JJ on_IN demand_NN ,_, less_JJR benefits_NNS obligation_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, until_IN all_DT disposal_NN obligations_NNS and_CC overdrafts_NNS repayable_JJ on_IN demand_NN :_: and_CC liquid_JJ there_EX is_VBZ no_DT such_JJ requirement_NN ._.
resources_NNS comprise_VBP current_JJ asset_NN investments_NNS held_VBD as_IN readily_RB disposable_JJ stores_NNS Restructuring_VBG costs_NNS Current_JJ assets_NNS and_CC liabilities_NNS of_IN value_NN ._.
Under_IN SFAS_NNP 95_CD cash_NN equivalents_NNS ,_, Under_IN UK_NNP GAAP_NNP ,_, provisions_NNS are_VBP made_VBN for_IN In_IN the_DT Groups_NNS Financial_NNP Statements_NNP prepared_VBD comprising_VBG short_JJ term_NN highly_RB liquid_JJ restructuring_NN costs_NNS once_RB a_DT detailed_JJ formal_JJ plan_NN under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT investments_NNS ,_, generally_RB with_IN original_JJ maturities_NNS is_VBZ in_IN place_NN and_CC valid_JJ expectations_NNS have_VBP been_VBN share_NN options_NNS awarded_VBN to_TO employees_NNS under_IN of_IN three_CD months_NNS or_CC less_JJR ,_, are_VBP grouped_VBN together_RB raised_VBN in_IN those_DT affected_VBN that_IN the_DT restructuring_VBG the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN and_CC the_DT with_IN cash_NN :_: short_JJ term_NN borrowings_NNS repayable_JJ will_MD be_VB carried_VBN out_RP ._.
US_NNP GAAP_NNP requires_VBZ a_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN on_IN demand_NN would_MD not_RB be_VB included_VBN within_IN number_NN of_IN specific_JJ criteria_NNS to_TO be_VB met_VBN before_IN Plan_NN as_IN the_DT exercise_NN price_NN is_VBZ equivalent_JJ to_TO the_DT cash_NN and_CC cash_NN equivalents_NNS and_CC movements_NNS such_JJ costs_NNS can_MD be_VB recognized_VBN as_IN an_DT expense_NN ._.
market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN US_NNP on_IN those_DT borrowings_NNS would_MD be_VB included_VBN in_IN Among_IN these_DT are_VBP the_DT requirements_NNS that_WDT costs_VBZ GAAP_NNP ,_, the_DT cost_NN is_VBZ calculated_VBN as_IN the_DT financing_NN activities_NNS ._.
associated_VBN with_IN exit_NN or_CC disposal_NN activities_NNS difference_NN between_IN the_DT option_NN price_NN and_CC the_DT are_VBP recognized_VBN when_WRB the_DT costs_NNS are_VBP incurred_VBN market_NN price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, for_IN New_NNP accounting_NN standards_NNS rather_RB than_IN at_IN the_DT date_NN of_IN commitment_NN to_TO an_DT variable_JJ plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN SFAS_NNP 143_CD Accounting_NN for_IN Asset_NNP Retirement_NNP exit_NN or_CC disposal_NN plan_NN ._.
To_TO the_DT extent_NN that_IN period_NN until_IN measurement_NN date_NN ._.
Under_IN the_DT Obligation_NNP addresses_VBZ the_DT accounting_NN and_CC restructuring_NN costs_NNS are_VBP related_VBN to_TO the_DT activities_NNS requirements_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
25_CD any_DT reporting_NN for_IN obligations_NNS associated_VBN with_IN the_DT of_IN the_DT acquired_VBN company_NN ,_, US_NNP GAAP_NNP allows_VBZ compensation_NN cost_NN would_MD be_VB amortised_VBN over_IN retirement_NN of_IN long-lived_JJ assets_NNS and_CC the_DT them_PRP to_TO be_VB recognized_VBN as_IN a_DT liability_NN upon_IN the_DT period_NN from_IN the_DT date_NN the_DT options_NNS are_VBP associated_VBN asset_NN retirement_NN costs_NNS ._.
granted_VBN to_TO the_DT date_NN they_PRP are_VBP first_JJ exercisable_JJ ._.
effective_JJ for_IN accounting_NN periods_NNS beginning_VBG on_IN Under_IN US_NNP GAAP_NNP ,_, in_IN the_DT net_JJ income_NN or_CC after_IN 15_CD June_NNP 2002_CD ._.
The_DT adoption_NN of_IN SFAS_NNP Software_NNP costs_VBZ reconciliation_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN for_IN 143_CD did_VBD not_RB have_VB a_DT material_NN effect_NN on_IN the_DT Under_IN UK_NNP GAAP_NNP ,_, AstraZeneca_NNP capitalises_VBZ stock_NN compensation_NN costs_NNS calculated_VBN under_IN results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
certain_JJ defined_VBN software_NN costs_NNS and_CC amortises_NNS APB_NNP Opinion_NNP No._NN ._.
Under_IN US_NNP GAAP_NNP ,_, SFAS_NNP 146_CD Accounting_NN for_IN Costs_NNS Associated_NNP software_NN costs_NNS are_VBP generally_RB capitalized_VBN and_CC Statement_NNP of_IN cash_NN flows_NNS :_: Basis_NN of_IN with_IN Exit_NN or_CC Disposal_NNP Activities_NNPS ,_, issued_VBN on_IN 30_CD amortised_VBN over_IN three_CD to_TO five_CD years_NNS ._.
preparation_NN July_NNP 2002_CD ,_, requires_VBZ costs_NNS associated_VBN with_IN exit_NN AstraZenecas_NNP statement_NN of_IN Group_NNP cash_NN flow_NN or_CC disposal_NN activities_NNS to_TO be_VB recognized_VBN when_WRB Foreign_NNP exchange_NN is_VBZ prepared_VBN in_IN accordance_NN with_IN UK_NNP Financial_NNP the_DT costs_NNS are_VBP incurred_VBN rather_RB than_IN at_IN the_DT date_NN Under_IN UK_NNP GAAP_NNP ,_, unrealised_JJ gains_NNS and_CC losses_NNS Reporting_NNP Standard_NNP 1_CD Revised_VBN 1996_CD FRS_NNP of_IN commitment_NN to_TO an_DT exit_NN or_CC disposal_NN plan_NN ._.
on_IN foreign_JJ currency_NN transactions_NNS to_TO hedge_VB 1_CD ,_, whose_WP$ objective_NN and_CC principles_NNS are_VBP similar_JJ The_DT provisions_NNS are_VBP effective_JJ for_IN disposals_NNS anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, foreign_JJ to_TO those_DT set_VBN out_RP in_IN SFAS_NNP 95_CD ,_, Statement_NN of_IN initiated_VBN after_IN 31_CD December_NNP 2002_CD and_CC currency_NN transactions_NNS may_MD be_VB deferred_VBN and_CC Cash_NNP Flows_NNP ._.
The_DT principal_JJ differences_NNS restatement_NN of_IN prior_JJ periods_NNS is_VBZ not_RB required_VBN ._.
accounted_VBD for_IN at_IN the_DT same_JJ time_NN as_IN the_DT between_IN the_DT standards_NNS relate_VBP to_TO The_DT adoption_NN of_IN SFAS_NNP 146_CD did_VBD not_RB have_VB a_DT anticipated_JJ transactions_NNS ._.
Under_IN FRS_NNP 1_CD ,_, the_DT Company_NN material_NN effect_NN on_IN the_DT results_NNS or_CC net_JJ assets_NNS of_IN such_JJ deferral_JJ is_VBZ not_RB permitted_VBN except_IN in_IN presents_VBZ its_PRP$ cash_NN flows_VBZ for_IN a_DT operating_NN AstraZeneca_NNP and_CC there_EX was_VBD no_DT impact_NN on_IN certain_JJ defined_VBN circumstances_NNS ._.
activities_NNS :_: b_NN dividends_NNS received_VBN from_IN joint_JJ prior_JJ periods_NNS ._.
ventures_NNS and_CC associates_NNS :_: c_NN returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN :_: AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNP 115_CD New_NNP accounting_NN standards_NNS FIN_NNP No._NN ._.
46R_CD Consolidation_NN of_IN Variable_JJ continued_VBN Interest_NN Entities_NNS is_VBZ intended_VBN to_TO address_VB perceived_VBN weaknesses_NNS in_IN accounting_NN for_IN SFAS_NNP No._NN ._.
148_CD Accounting_NN for_IN Stock_NNP Based_VBD special_JJ purpose_NN or_CC off-balance_JJ sheet_NN entities_NNS Compensation_NNP Transition_NN and_CC Disclosure_NN and_CC provides_VBZ guidance_NN on_IN identifying_VBG the_DT an_DT Amendment_NNP of_IN FASB_NNP Statement_NNP No._NN ._.
123_CD party_NN with_IN a_DT controlling_VBG financial_JJ interest_NN permits_VBZ two_CD additional_JJ transition_NN methods_NNS for_IN resulting_VBG from_IN arrangements_NNS or_CC financial_JJ entities_NNS that_WDT change_VBP from_IN the_DT intrinsic_JJ method_NN interests_NNS as_IN opposed_VBN to_TO voting_VBG rights_NNS ._.
If_IN a_DT to_TO the_DT fair_JJ value_NN based_VBN method_NN of_IN accounting_VBG party_NN has_VBZ a_DT controlling_VBG financial_JJ interest_NN in_IN a_DT for_IN stock-based_JJ employee_NN compensation_NN ._.
variable_JJ interest_NN entity_NN VIE_NNP then_RB the_DT assets_NNS ,_, The_DT statement_NN also_RB requires_VBZ new_JJ disclosures_NNS liabilities_NNS and_CC results_NNS of_IN the_DT VIE_NNP should_MD be_VB including_VBG the_DT ramp-up_JJ effect_NN of_IN adopting_VBG fair_JJ included_VBN in_IN the_DT consolidated_JJ financial_JJ value_NN based_VBN accounting_NN for_IN stock-based_JJ statements_NNS of_IN the_DT party_NN ._.
FIN46R_CD applied_VBN to_TO all_DT employee_NN compensation_NN on_IN reported_VBN results_NNS VIEs_NNS or_CC potential_JJ VIEs_NNS referred_VBD to_TO as_IN special_JJ and_CC that_IN those_DT effects_NNS be_VB disclosed_VBN more_RBR purpose_NN entities_NNS for_IN periods_NNS ending_VBG on_IN or_CC prominently_RB by_IN specifying_VBG the_DT form_NN ,_, content_NN after_IN 15_CD December_NNP 2003_CD ._.
Adoption_NN for_IN all_DT and_CC location_NN of_IN those_DT disclosures_NNS ._.
The_DT other_JJ entities_NNS is_VBZ required_VBN for_IN periods_NNS ending_VBG transition_NN guidance_NN and_CC annual_JJ disclosure_NN on_IN or_CC after_IN 15_CD March_NNP 2004_CD ._.
FIN46R_CD has_VBZ not_RB ,_, provisions_NNS of_IN SFAS_NNP No._NN ._.
148_CD are_VBP effective_JJ for_IN and_CC is_VBZ not_RB expected_VBN to_TO have_VB ,_, a_DT material_NN effect_NN fiscal_JJ years_NNS ending_VBG after_IN 15_CD December_NNP 2002_CD ._.
on_IN the_DT results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
AstraZeneca_NNP has_VBZ not_RB adopted_VBN the_DT fair_JJ value_NN based_VBN method_NN of_IN accounting_NN for_IN stockSFAS_NNP No._NN ._.
132_CD Revised_VBN 2003_CD Employers_NNS based_VBN employee_NN compensation_NN and_CC ,_, Disclosures_NNS about_IN Pensions_NNS and_CC Other_JJ Posttherefore_NNP ,_, is_VBZ not_RB subject_JJ to_TO the_DT transition_NN Retirement_NNP Benefits_NNPS was_VBD issued_VBN on_IN 23_CD provisions_NNS of_IN SFAS_NNP No._NN ._.
December_NNP 2003_CD and_CC is_VBZ effective_JJ ,_, subject_JJ to_TO certain_JJ exemptions_NNS ,_, for_IN fiscal_JJ years_NNS ending_VBG on_IN SFAS_NNP No._NN ._.
149_CD Amendment_NNP of_IN Statement_NNP or_CC after_IN 15_CD December_NNP 2003_CD ._.
AstraZeneca_NNP 133_CD on_IN Derivative_JJ Instruments_NNPS and_CC Hedging_NNP has_VBZ complied_VBN with_IN the_DT new_JJ requirements_NNS in_IN Activities_NNS that_WDT was_VBD issued_VBN on_IN 30_CD April_NNP 2003_CD ,_, this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ amends_NNS and_CC clarifies_VBZ accounting_NN for_IN certain_JJ Information_NN ._.
derivative_JJ instruments_NNS particularly_RB contracts_NNS with_IN certain_JJ embedded_VBN derivative_NN instruments_NNS and_CC hedging_VBG activities_NNS under_IN SFAS_NNP No._NN ._.
133_CD Accounting_NN for_IN Derivative_JJ Instruments_NNPS and_CC Hedging_NNP Activities_NNPS ._.
Except_IN where_WRB its_PRP$ provisions_NNS clarify_VBP SFAS_NNP No._NN ._.
133_CD implementation_NN issues_NNS previously_RB effective_JJ ,_, the_DT standard_JJ applies_VBZ prospectively_RB for_IN contracts_NNS entered_VBN into_IN ,_, and_CC hedging_VBG activities_NNS designated_VBN after_IN ,_, 30_CD June_NNP 2003_CD ._.
149_CD did_VBD not_RB have_VB a_DT material_NN effect_NN on_IN the_DT results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 116_CD Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Net_JJ income_NN As_IN a_DT result_NN of_IN the_DT significant_JJ difference_NN between_IN the_DT UK_NNP GAAP_NNP and_CC US_NNP GAAP_NNP treatment_NN of_IN the_DT combination_NN of_IN Astra_NNP and_CC Zeneca_NNP in_IN the_DT year_NN of_IN acquisition_NN ,_, and_CC in_IN the_DT results_NNS of_IN preceding_VBG periods_NNS ,_, condensed_JJ statements_NNS of_IN operations_NNS and_CC cash_NN flow_NN under_IN US_NNP GAAP_NNP have_VBP been_VBN prepared_VBN for_IN the_DT benefit_NN of_IN US_NNP investors_NNS ._.
The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO net_JJ income_NN and_CC shareholders_NNS equity_NN which_WDT would_MD have_VB been_VBN required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ statements_NNS of_IN income_NN before_IN exceptional_JJ items_NNS 3,036_CD 3,186_CD 3,044_CD Exceptional_JJ items_NNS after_IN tax_NN 350_CD 138_CD Net_JJ income_NN for_IN the_DT period_NN under_IN UK_NNP GAAP_NNP 3,036_CD 2,836_CD 2,906_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Amortisation_NNP and_CC other_JJ acquisition_NN adjustments_NNS 952_CD 864_CD 1,514_CD Others_NNS 59_CD 55_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 17_CD 46_CD 57_CD Deferred_JJ taxation_NN On_IN fair_JJ values_NNS of_IN Astra_NNP 266 239 249_CD Others_NNS 91_CD 99_CD 198_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS expense_NN 43_CD 46_CD 29_CD Software_NNP costs_NNS 18_CD 46_CD 10_CD Restructuring_NN costs_NNS 22_CD Share_NN based_VBN compensation_NN 12_CD 33_CD 7_CD Fair_NNP value_NN of_IN derivative_JJ financial_JJ instruments_NNS 10_CD 93_CD 18_CD Deferred_JJ income_NN recognition_NN 14_CD 61_CD 75_CD Unrealised_JJ losses_NNS on_IN foreign_JJ exchange_NN and_CC others_NNS 18_CD 1_CD 10_CD Net_JJ income_NN before_IN cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN 2,268_CD 2,307_CD 1,365_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN ,_, net_NN of_IN tax_NN ,_, on_IN adoption_NN of_IN SFAS_NNP No._NN ._.
133_CD 32_CD Net_JJ income_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 2,268_CD 2,307_CD 1,397_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS 117_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Operations_NNP 2003 2002 2001_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 18,849_CD 17,841_CD 16,222_CD Cost_NN of_IN sales_NNS 4,469_CD 4,520_CD 4,198_CD Distribution_NN costs_NNS 162 141 122_CD Research_NNP and_CC development_NN 3,451_CD 3,069_CD 2,687_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 6,941_CD 6,165_CD 5,219_CD Acquisition_NNP related_VBN costs_NNS 224_CD Amortisation_NNP of_IN intangibles_NNS and_CC goodwill_NN 881_CD 1,052_CD 1,769_CD Other_JJ income_NN 225 308 283_CD Operating_NN income_NN 3,170_CD 3,202_CD 2,286_CD Net_JJ interest_NN income_NN 63 140 188_CD Income_NN from_IN continuing_VBG operations_NNS before_IN taxation_NN 3,233_CD 3,342_CD 2,474_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 965_CD 1,035_CD 1,109_CD Net_JJ income_NN from_IN continuing_VBG operations_NNS 2,268_CD 2,307_CD 1,365_CD Net_JJ income_NN before_IN cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN 2,268_CD 2,307_CD 1,365_CD Cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN policy_NN on_IN adoption_NN of_IN SFAS_NNP No._NN ._.
133_CD 32_CD Net_JJ income_NN for_IN the_DT year_NN 2,268_CD 2,307_CD 1,397_CD Weighted_VBN average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,709_CD 1,733_CD 1,758_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 3_CD 23_CD Diluted_NNP weighted_JJ average_JJ number_NN of_IN $_$ 0.25_CD Ordinary_NNP Shares_NNP in_IN accordance_NN with_IN US_NNP GAAP_NNP millions_NNS 1,712_CD 1,735_CD 1,761_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS before_IN change_NN in_IN accounting_NN policy_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ 1.33_CD $_$ 1.33_CD $_$ 0.77_CD Net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS after_IN change_NN in_IN accounting_NN policy_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_JJ $_$ 1.33_CD $_$ 1.33_CD $_$ 0.79_CD US_NNP GAAP_NNP Statement_NN of_IN Comprehensive_NNP Income_NNP 2003 2002 2001_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN for_IN the_DT year_NN 2,268_CD 2,307_CD 1,397_CD Exchange_NNP gains_NNS losses_NNS net_NN of_IN tax_NN 3,635_CD 2,919_CD 1,473_CD Other_JJ movements_NNS ,_, net_NN of_IN tax_NN 100_CD 73_CD Total_JJ Comprehensive_NNP Income_NNP 5,803_CD 5,153_CD 76_CD Other_JJ movements_NNS in_IN 2003_CD include_VBP the_DT recognition_NN of_IN a_DT minimum_JJ liability_NN under_IN SFAS_NNP No._NN ._.
87_CD Employers_NNS Accounting_NN for_IN Pensions_NNS of_IN $_$ 177m_CD ._.
Tax_NNP effects_NNS on_IN exchange_NN gains_NNS losses_NNS were_VBD $_$ 297_CD m_NN and_CC on_IN other_JJ movements_NNS $_$ 67m_CD ._.
The_DT cumulative_JJ exchange_NN gains_NNS and_CC losses_NNS net_NN of_IN tax_NN on_IN the_DT translation_NN of_IN foreign_JJ currency_NN financial_JJ statements_NNS under_IN US_NNP GAAP_NNP are_VBP set_VBN out_RP in_IN the_DT following_JJ note_NN :_: 2003 2002 2001_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Balance_NN at_IN 1_CD January_NNP 1,399_CD 4,318_CD 2,845_CD Movement_NNP in_IN year_NN 3,635_CD 2,919_CD 1,473_CD Balance_NN at_IN 31_CD December_NNP 2,236_CD 1,399_CD 4,318_CD The_DT cumulative_JJ other_JJ movements_NNS net_NN of_IN tax_NN at_IN 31_CD December_NNP 2003_CD was_VBD a_DT charge_NN of_IN $_$ 154m_CD 2002_CD $_$ 73m_CD ,_, 2001_CD $_$ nil_JJ ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 118_CD Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Stock_NNP compensation_NN In_IN the_DT Groups_NNS Financial_NNP Statements_NNP prepared_VBD under_IN UK_NNP GAAP_NNP ,_, no_DT cost_NN is_VBZ accrued_VBN for_IN the_DT share_NN options_NNS awarded_VBN to_TO employees_NNS under_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ,_, and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN as_IN the_DT exercise_NN price_NN is_VBZ equivalent_JJ to_TO the_DT market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN US_NNP GAAP_NNP the_DT cost_NN is_VBZ calculated_VBN as_IN the_DT difference_NN between_IN the_DT option_NN price_NN and_CC the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN or_CC ,_, for_IN variable_JJ plans_NNS ,_, at_IN the_DT end_NN of_IN the_DT reporting_NN period_NN until_IN measurement_NN date_NN ._.
Under_IN the_DT requirements_NNS of_IN APB_NNP Opinion_NNP No._NN ._.
25_CD any_DT compensation_NN cost_NN would_MD be_VB amortised_VBN over_IN the_DT period_NN from_IN the_DT date_NN the_DT options_NNS are_VBP granted_VBN to_TO the_DT date_NN they_PRP are_VBP first_JJ exercisable_JJ ._.
Under_IN US_NNP GAAP_NNP in_IN the_DT net_JJ income_NN reconciliation_NN ,_, the_DT Group_NNP has_VBZ adjusted_VBN for_IN stock_NN compensation_NN costs_NNS as_IN calculated_VBN under_IN APB_NNP Opinion_NNP No._NN ._.
123_CD Accounting_NN for_IN Stock-Based_NNP Compensation_NNP sets_VBZ out_RP an_DT alternative_JJ methodology_NN for_IN recognizing_VBG the_DT compensation_NN cost_NN based_VBN on_IN the_DT fair_JJ value_NN at_IN grant_NN date_NN ._.
Had_VBD the_DT Group_NNP adopted_VBD this_DT methodology_NN ,_, the_DT incremental_JJ effect_NN on_IN net_JJ income_NN under_IN US_NNP GAAP_NNP is_VBZ shown_VBN below_IN :_: 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP as_IN reported_VBN 2,268_CD 2,307_CD 1,397_CD Compensation_NNP cost_NN under_IN APB_NNP No._NN ._.
25_CD 12_CD 33_CD 7_CD Compensation_NNP cost_NN under_IN SFAS_NNP No._NN ._.
123 154 122_CD 83_CD Pro_FW forma_FW net_JJ income_NN 2,126_CD 2,152_CD 1,321_CD Pro_FW forma_FW net_JJ income_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NN and_CC ADS_NNPS in_IN accordance_NN with_IN US_NNP GAAP_NNP basic_JJ and_CC diluted_VBN :_: As_IN reported_VBN $_$ 1.33_CD $_$ 1.33_CD $_$ 0.79_CD Pro_FW forma_FW $_$ 1.24_CD $_$ 1.24_CD $_$ 0.75_CD The_DT fair_JJ value_NN of_IN options_NNS granted_VBN is_VBZ estimated_VBN ,_, based_VBN on_IN the_DT stock_NN price_NN at_IN the_DT grant_NN date_NN ,_, using_VBG the_DT Black-Scholes_NNP option_NN pricing_NN model_NN with_IN the_DT following_VBG assumptions_NNS :_: 2003 2002 2001_CD Dividend_NN yield_NN 2.0_CD %_NN 1.6_CD %_NN 1.5_CD %_NN Expected_VBN volatility_NN 25.0_CD %_NN 30.0_CD %_NN 20.0_CD %_NN Risk-free_JJ interest_NN rate_NN 4.3_CD %_NN 5.2_CD %_NN 4.2_CD %_NN Expected_VBN lives_NNS :_: AstraZeneca_NNP Share_NNP Option_NN Plan_NN 6.0_CD years_NNS 6.0_CD years_NNS 6.0_CD years_NNS Expected_VBN lives_NNS :_: SAYE_NNP Plan_NNP 4.3_CD years_NNS 4.3_CD years_NNS 4.3_CD years_NNS In_IN the_DT initial_JJ phase-in_JJ period_NN ,_, the_DT effects_NNS of_IN applying_VBG SFAS_NNP No._NN ._.
123_CD for_IN disclosing_VBG compensation_NN cost_NN may_MD not_RB be_VB representative_NN of_IN the_DT effects_NNS on_IN pro_FW forma_FW net_JJ income_NN and_CC earnings_NNS per_IN share_NN for_IN future_JJ years_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNP 119_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Pension_NN and_CC post-retirement_NN benefits_NNS For_IN the_DT purposes_NNS of_IN US_NNP GAAP_NNP ,_, the_DT pension_NN costs_NNS of_IN the_DT major_JJ UK_NNP retirement_NN plan_NN and_CC of_IN the_DT retirement_NN plans_NNS of_IN the_DT major_JJ non-UK_JJ subsidiaries_NNS have_VBP been_VBN restated_VBN in_IN the_DT following_VBG tables_NNS in_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP 132_CD ._.
These_DT plans_NNS comprise_VBP a_DT substantial_JJ portion_NN of_IN the_DT actuarial_JJ liabilities_NNS of_IN all_DT AstraZeneca_NNP retirement_NN plans_NNS ._.
The_DT changes_NNS in_IN projected_VBN benefit_NN obligations_NNS ,_, plan_NN assets_NNS and_CC details_NNS of_IN the_DT funded_JJ status_NN of_IN these_DT retirement_NN plans_NNS ,_, together_RB with_IN the_DT changes_NNS in_IN the_DT accumulated_VBN other_JJ post-retirement_JJ benefit_NN obligations_NNS ,_, under_IN SFAS_NNP 132are_CD as_IN follows_VBZ :_: Other_JJ Pension_NNP post-retirement_NN benefits_NNS benefits_NNS Change_NNP in_IN projected_VBN benefit_NN obligation_NN 2003 2002 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Benefit_NNP obligation_NN at_IN beginning_NN of_IN year_NN 5,026_CD 4,337_CD 210_CD 205_CD Service_NNP cost_NN 123_CD 114_CD 9_CD 8_CD Interest_NN cost_NN 290_CD 263_CD 14_CD 14_CD Participant_NN contributions_NNS 22_CD 18_CD 1_CD Actuarial_JJ loss_NN 508_CD 80_CD 24_CD 23_CD Special_JJ termination_NN benefits_NNS 12_CD Settlement_NNP and_CC curtailment_NN 4_CD 24_CD Benefits_NNS paid_VBN 226_CD 206_CD 19_CD 19_CD Exchange_NNP 495_CD 408_CD 3_CD 3_CD Benefit_NNP obligation_NN at_IN end_NN of_IN year_NN 6,242_CD 5,026_CD 242_CD 210_CD Other_JJ Pension_NNP post-retirement_NN benefits_NNS benefits_NNS Change_NNP in_IN plan_NN assets_NNS 2003 2002 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Fair_NN value_NN at_IN beginning_NN of_IN year_NN 4,038_CD 3,753_CD 133_CD Actual_JJ return_NN on_IN plan_NN assets_NNS 551_CD 142_CD 35_CD 16_CD Group_NNP contribution_NN 383_CD 284_CD 43_CD 161_CD Participant_NN contributions_NNS 22_CD 18_CD 1_CD Settlement_NNP and_CC curtailment_NN Benefits_NNS paid_VBD 226_CD 206_CD 17_CD 12_CD Exchange_NNP 406_CD 331_CD Fair_NNP value_NN of_IN plan_NN assets_NNS at_IN end_NN of_IN year_NN 5,174_CD 4,038_CD 195_CD 133_CD Funded_VBN status_NN of_IN plans_NNS 1,068_CD 988_CD 47_CD 77_CD Unrecognised_JJ net_JJ loss_NN 1,220_CD 938_CD 65_CD Prior_RB service_NN cost_NN not_RB recognized_VBN 35_CD 29_CD 9_CD Unrecognised_JJ net_JJ obligation_NN on_IN implementation_NN 3_CD 187_CD 18_CD 9_CD 77_CD Adjustments_NNS to_TO recognize_VB minimum_JJ liability_NN :_: Intangible_JJ assets_NNS 39_CD 45_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 221_CD 45_CD Accrued_VBN benefit_NN asset_NN liability_NN 73_CD 108_CD 9_CD 77_CD At_IN 31_CD December_NNP 2003_CD ,_, the_DT projected_VBN benefit_NN obligation_NN ,_, accumulated_VBN benefit_NN obligation_NN and_CC fair_JJ value_NN of_IN the_DT plan_NN assets_NNS in_IN respect_NN of_IN the_DT pension_NN plans_NNS above_IN with_IN accumulated_VBN benefit_NN obligations_NNS in_IN excess_NN of_IN plan_NN assets_NNS were_VBD $_$ 5,287_CD m_NN ,_, $_$ 4,524_CD m_NN and_CC $_$ 4,249_CD m_NN ,_, 2002_CD $_$ 4,249_CD m_NN ,_, $_$ 3,557_CD m_NN and_CC $_$ 3,296_CD m_NN respectively_RB ._.
The_DT total_JJ accumulated_VBN benefit_NN obligations_NNS for_IN the_DT pension_NN plans_NNS was_VBD $_$ 5,318_CD m_NN 2002_CD $_$ 4,214_CD m._FW The_DT measurement_NN date_NN for_IN the_DT plan_NN assets_NNS and_CC benefit_NN obligations_NNS set_VBN out_RP above_IN was_VBD 31_CD December_NNP 2003_CD ._.
Contributions_NNS to_TO the_DT plans_NNS in_IN 2004_CD are_VBP estimated_VBN to_TO be_VB $_$ 111m_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 120_CD Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Assumed_JJ discount_NN rates_NNS and_CC rates_NNS of_IN increase_NN in_IN remuneration_NN used_VBN in_IN calculating_VBG the_DT projected_VBN benefit_NN obligations_NNS together_RB with_IN long_JJ term_NN rates_NNS of_IN return_NN on_IN plan_NN assets_NNS vary_VBP according_VBG to_TO the_DT economic_JJ conditions_NNS of_IN the_DT country_NN in_IN which_WDT the_DT retirement_NN plans_NNS are_VBP situated_VBN ._.
The_DT weighted_JJ average_NN rates_NNS used_VBN for_IN calculation_NN of_IN year_NN end_NN benefit_NN obligations_NNS and_CC forecast_NN benefit_NN cost_NN in_IN the_DT main_JJ retirement_NN plans_NNS and_CC other_JJ benefit_NN obligations_NNS for_IN SFAS_NNP 132_CD purposes_NNS were_VBD as_IN follows_VBZ :_: Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2003 2002 2001 2003_CD 2002_CD 2001_CD %_NN %_NN %_NN %_NN %_NN %_NN Discount_NNP rate_NN 5.5_CD 5.8_CD 6.0_CD 5.9_CD 6.6_CD 7.1_CD Long_JJ term_NN rate_NN of_IN increase_NN in_IN remuneration_NN 4.0_CD 4.1_CD 4.4_CD 5.0_CD 4.8_CD n_NN a_DT Expected_VBN long_JJ term_NN return_NN on_IN assets_NNS 6.6_CD 6.4_CD 6.5_CD 7.8_CD 7.8_CD n_NN a_DT The_DT Group_NNP has_VBZ assumed_VBN a_DT long_JJ term_NN rate_NN of_IN increase_NN in_IN healthcare_NN costs_NNS of_IN 10_CD %_NN ,_, reducing_VBG to_TO 5_CD %_NN ._.
Pension_NN benefits_NNS Other_JJ post-retirement_NN benefits_NNS 2003 2002 2001 2003_CD 2002_CD 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Net_JJ periodic_JJ cost_NN Service_NNP cost_NN present_JJ value_NN of_IN benefits_NNS accruing_VBG during_IN the_DT year_NN 123 114 102_CD 9_CD 87_CD Interest_NN cost_NN on_IN projected_VBN benefit_NN obligations_NNS 290 263 243_CD 14_CD 14_CD 14_CD Expected_VBN return_NN on_IN assets_NNS 280 263 242_CD 14_CD Net_JJ amortisation_NN and_CC deferral_JJ 34_CD 28_CD 39_CD 2_CD 1_CD 2_CD Net_JJ periodic_JJ cost_NN for_IN the_DT year_NN 167 142 142_CD 11_CD 21_CD 19_CD It_PRP is_VBZ estimated_VBN that_IN a_DT one_CD percentage_NN point_NN change_NN in_IN the_DT weighted_JJ average_JJ healthcare_NN costs_NNS trend_NN would_MD have_VB the_DT following_JJ effects_NNS on_IN the_DT accumulated_VBN benefit_NN obligation_NN and_CC net_JJ periodic_JJ cost_NN at_IN 31_CD December_NNP 2003_CD :_: One_CD percentage_NN point_NN Increase_VBP Decrease_NN $_$ m_CD $_$ m_CD Accumulated_VBN benefit_NN obligation_NN 13_CD 11_CD Net_JJ periodic_JJ cost_NN 2_CD 2_CD The_DT weighted_JJ average_JJ allocation_NN of_IN pension_NN and_CC other_JJ post-retirement_JJ plan_NN assets_NNS was_VBD as_IN follows_VBZ :_: 2003_CD 2002_CD %_NN %_NN Equities_NNS 49.2_CD 40.6_CD Bonds_NNS 48.8_CD 56.5_CD Other_JJ 2.0_CD 2.9_CD The_DT benefits_NNS expected_VBN to_TO be_VB paid_VBN in_IN the_DT future_NN are_VBP as_IN follows_VBZ :_: $_$ m_CD 2004 267 2005 275_CD 2006 284 2007 293_CD 2008 302 2009 2013_CD 1,695_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS 121_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Taxation_NNP 2003 2002 2001_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS UK_NNP taxation_NN Corporation_NNP tax_NN 138 165 147_CD Double_RB taxation_NN relief_NN 23_CD 7_CD 4_CD Deferred_VBN taxation_NN 88_CD 40_CD 10_CD Overseas_JJ taxation_NN Overseas_JJ taxes_NNS 878 921 831_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 35_CD 51_CD 30_CD Deferred_JJ taxation_NN 151_CD 33_CD 95_CD Share_NN of_IN taxation_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS Taxes_NNS on_IN income_NN from_IN continuing_VBG operations_NNS 965_CD 1,035_CD 1,109_CD The_DT table_NN below_IN reconciles_NNS the_DT UK_NNP statutory_JJ tax_NN charge_NN to_TO the_DT Groups_NNS actual_JJ charge_NN on_IN income_NN from_IN continuing_VBG operations_NNS ._.
2003 2002 2001_CD Years_NNS ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Income_NN on_IN continuing_VBG operations_NNS 3,233_CD 3,342_CD 2,506_CD Taxation_NNP charge_NN at_IN UK_NNP corporation_NN tax_NN rate_NN of_IN 30_CD %_NN for_IN 2003_CD 30_CD %_NN for_IN 2002_CD ,_, 30_CD %_NN for_IN 2001_CD 970_CD 1,002_CD 751_CD Differences_NNS in_IN effective_JJ overseas_JJ tax_NN rates_NNS 41_CD 648_CD Items_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 89_CD 83_CD 352_CD Items_NNS not_RB chargeable_JJ for_IN tax_NN purposes_NNS 88_CD 110_CD 76_CD Adjustments_NNS in_IN respect_NN of_IN prior_JJ periods_NNS 35_CD 51_CD 30_CD Exceptional_JJ items_NNS 105_CD 4_CD Tax_NNP on_IN income_NN from_IN continuing_VBG operations_NNS 965_CD 1,035_CD 1,109_CD In_IN 2003_CD ,_, claims_VBZ amounting_VBG to_TO $_$ 95m_CD 2002_CD $_$ 43m_CD for_IN tax_NN relief_NN arising_VBG as_IN a_DT result_NN of_IN a_DT restructuring_NN of_IN the_DT AMI_NNP joint_JJ venture_NN in_IN 1998_CD were_VBD made_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT reliefs_NNS are_VBP adjusted_VBN against_IN the_DT goodwill_NN arising_VBG on_IN the_DT restructuring_NN and_CC included_VBD in_IN other_JJ adjustments_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN 122_CD Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS Additional_JJ Information_NN for_IN US_NNP Investors_NNPS continued_VBD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD Shareholders_NNS equity_NN 2003_CD 2002_CD $_$ m_CD $_$ m_CD Total_JJ shareholders_NNS equity_NN under_IN UK_NNP GAAP_NNP 13,178_CD 11,172_CD Adjustments_NNS to_TO conform_VB to_TO US_NNP GAAP_NNP Purchase_NN accounting_NN adjustments_NNS including_VBG goodwill_NN and_CC intangibles_VBZ Deemed_JJ acquisition_NN of_IN Astra_NNP Goodwill_NNP 14,311_CD 12,692_CD Tangible_JJ and_CC intangible_JJ fixed_VBN assets_NNS 7,661_CD 7,707_CD Others_NNS 145_CD 86_CD Capitalisation_NNP ,_, less_JJR disposals_NNS and_CC amortisation_NN of_IN interest_NN 255_CD 238_CD Deferred_JJ taxation_NN On_IN fair_JJ value_NN of_IN Astra_NNP 2,313_CD 2,305_CD Others_NNS 207_CD 159_CD Dividend_NN 914_CD 808_CD Pension_NN and_CC other_JJ post-retirement_JJ benefits_NNS expense_NN 534_CD 295_CD Software_NNP costs_NNS capitalized_JJ 46_CD 64_CD Fair_NNP value_NN of_IN derivative_JJ financial_JJ instruments_NNS 109_CD 99_CD Deferred_JJ income_NN recognition_NN 14_CD Others_NNS 89_CD 90_CD Shareholders_NNS equity_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP 33,654_CD 30,183_CD Acquired_VBN intangible_JJ assets_NNS Details_NNS of_IN the_DT carrying_VBG amounts_NNS of_IN intangible_JJ fixed_JJ assets_NNS and_CC past_JJ and_CC projected_VBD amortisation_NN expenses_NNS are_VBP set_VBN out_RP below_IN ._.
2003_CD 2002_CD Gross_NNP Gross_NNP carrying_VBG Accumulated_NNP carrying_VBG Accumulated_NNP amount_NN amortisation_NN amount_NN amortisation_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Product_NNP rights_NNS 13,733_CD 5,274_CD 12,058_CD 3,672_CD Marketing_NNP and_CC distribution_NN rights_NNS 1,659_CD 831_CD 1,513_CD 600_CD Software_NNP 462 305 354 241_CD Others_NNS 421 329 408 294_CD Total_JJ 16,275_CD 6,739_CD 14,333_CD 4,807_CD Aggregate_NNP amortisation_NN expense_NN $_$ m_CD For_IN year_NN ended_VBD 31_CD December_NNP 2003_CD 1,245_CD For_IN year_NN ended_VBD 31_CD December_NNP 2002_CD 1,154_CD For_IN year_NN ended_VBD 31_CD December_NNP 2001_CD 1,135_CD Estimated_VBN amortisation_NN expense_NN $_$ m_CD For_IN year_NN ended_VBD 31_CD December_NNP 2004_CD 1,228_CD For_IN year_NN ended_VBD 31_CD December_NNP 2005_CD 1,228_CD For_IN year_NN ended_VBD 31_CD December_NNP 2006_CD 1,216_CD For_IN year_NN ended_VBD 31_CD December_NNP 2007_CD 1,128_CD For_IN year_NN ended_VBD 31_CD December_NNP 2008_CD 1,128_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Additional_JJ Information_NN Form_NN 20-F_JJ Information_NN 2003_CD for_IN US_NNP Investors_NNPS 123_CD Differences_NNS between_IN UK_NNP and_CC US_NNP accounting_NN principles_NNS continued_VBD The_DT weighted_JJ average_JJ amortisation_NN period_NN in_IN respect_NN of_IN each_DT class_NN of_IN intangible_JJ asset_NN is_VBZ as_IN follows_VBZ :_: Product_NN rights_NNS 13_CD years_NNS Marketing_NNP and_CC distribution_NN rights_NNS 16_CD years_NNS Software_NNP 4_CD years_NNS Other_JJ 8_CD years_NNS Goodwill_NNP The_DT changes_NNS in_IN the_DT carrying_VBG amount_NN of_IN goodwill_NN for_IN the_DT two_CD years_NNS ended_VBN 31_CD December_NNP 2003_CD were_VBD as_IN follows_VBZ :_: $_$ m_CD Balance_NN as_IN at_IN 1_CD January_NNP 2002_CD 11,943_CD Acquired_VBN 62_CD Reclassification_NN of_IN assembled_VBN workforce_NN on_IN adoption_NN of_IN SFAS_NNP 141_CD 364_CD Exchange_NNP adjustments_NNS 1,278_CD Balance_NN as_IN at_IN 1_CD January_NNP 2003_CD 13,647_CD Acquired_VBN 1_CD Exchange_NNP adjustments_NNS 1,658_CD Balance_NN as_IN at_IN 31_CD December_NNP 2003_CD 15,306_CD Adoption_NN of_IN SFAS_NNP 142_CD in_IN 2002_CD resulted_VBD in_IN the_DT cessation_NN of_IN amortisation_NN of_IN goodwill_NN ._.
Had_VBD goodwill_NN not_RB been_VBN amortised_VBN in_IN 2001_CD ,_, net_JJ income_NN would_MD have_VB increased_VBN from_IN $_$ 1,397_CD m_NN to_TO $_$ 2,125_CD m_NN with_IN a_DT corresponding_JJ increase_NN in_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN from_IN $_$ 0.77_CD to_TO $_$ 1.21_CD ._.
US_NNP GAAP_NNP Condensed_NNP Consolidated_NNP Statement_NNP of_IN Cash_NNP Flows_NNP 2003 2002 2001_CD For_IN the_DT years_NNS ended_VBN 31_CD December_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS 3,416_CD 4,833_CD 3,126_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS 771 806 260_CD New_NNP fixed_JJ asset_NN investments_NNS 120_CD 1_CD 5_CD Disposal_NNP of_IN fixed_JJ assets_NNS 38_CD 66_CD 44_CD Acquisitions_NNS and_CC disposals_NNS 80_CD 44_CD Capital_NN expenditure_NN 1,515_CD 1,608_CD 1,582_CD Net_JJ cash_NN outflows_NNS from_IN investing_VBG activities_NNS 746_CD 2,349_CD 1,327_CD Net_JJ cash_NN flow_NN before_IN financing_VBG 2,670_CD 2,484_CD 1,799_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Equity_NNP dividends_NNS paid_VBD 1,222_CD 1,234_CD 1,236_CD Re-purchase_NN of_IN AstraZeneca_NNP PLC_NNP Ordinary_NNP Shares_NNP 1,107_CD 1,154_CD 994_CD Net_JJ decrease_NN increase_NN in_IN short_JJ term_NN borrowings_NNS 13_CD 7_CD Loans_NNS repaid_VBN new_JJ loans_NNS 345_CD 105_CD 28_CD Net_JJ cash_NN outflows_NNS from_IN financing_VBG activities_NNS 2,674_CD 2,506_CD 2,195_CD Decrease_NN in_IN cash_NN 4_CD 22_CD 396_CD Cash_NN :_: At_IN 1_CD January_NNP 524 510 908_CD Decrease_NN in_IN cash_NN 4_CD 22_CD 396_CD Exchange_NNP movements_NNS 61_CD 36_CD 2_CD At_IN 31_CD December_NNP 581 524 510_CD Interest_NN paid_VBN was_VBD $_$ 32m_CD in_IN 2003_CD ,_, $_$ 96m_CD in_IN 2002_CD and_CC $_$ 84m_CD in_IN 2001_CD ._.
